NeOnc Technologies Enhances Competitive Edge with Patents
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a pioneering biopharmaceutical company, has made significant strides by expanding its global patent portfolio to include a total of 176 patents. This expansion plays a crucial role in fortifying the company’s competitive position in the biopharmaceutical landscape.
Details of the Patent Portfolio
The current array of NeOnc’s intellectual property (IP) encompasses 126 issued patents, comprising 29 in the United States and 97 internationally, alongside 50 pending patents, 19 in the United States and 31 abroad. This robust portfolio demonstrates NeOnc's ongoing commitment to innovation and strategic planning.
Strategic Benefits of the Patent Portfolio
NeOnc's enhanced patent portfolio not only reflects its innovative capabilities but also helps to safeguard the commercial viability of its therapeutic candidates across global markets. The company’s IP protections stretch over all major pharmaceutical regions, including the U.S., European Union, China, Japan, Brazil, and Australia. These protections are especially vital as NeOnc advances its next-generation therapeutics toward regulatory approval.
Statements from Leadership
“Intellectual property is at the heart of our strategic approach,” stated Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “The depth of our patent portfolio underscores our commitment to innovation and expands our ambition in developing groundbreaking solutions for patients.”
Overview of Lead Programs
NeOnc's lead programs, including NEO100, NEO212, NEO214, and NEO400, enjoy extensive patent protection, ensuring these therapeutics remain at the forefront of the industry. Key highlights include:
- NEO100: This ultrapure perillyl alcohol is bolstered by eight U.S. patents expiring between 2031 and 2036, with possibilities for extensions through the FDA’s patent term extension program and the additional exclusivity associated with its Orphan Drug Designation.
- NEO212 and NEO214: These structurally unique perillyl alcohol conjugates qualify for Orange Book eligibility and benefit from new chemical entity data exclusivity following approval.
- NEO400: This topical anticancer agent has recently secured broad patent coverage across Europe, with similar applications currently in process worldwide.
- Furthermore, NeOnc holds key patents for its compounds that effectively permeabilize the blood-brain barrier, with protections extending into 2039.
Commitment to Patient-Centric Innovation
Dr. Thomas Chen, CEO of NeOnc Technologies, emphasized the company's mission, stating, “Our objective is to deliver transformative therapies to patients facing some of the most challenging health conditions. Our expanding patent estate provides a solid platform to achieve that goal.” This commitment underscores NeOnc’s determination to aggressively invest in intellectual property as it seeks to reach critical clinical and regulatory benchmarks within its development pipeline.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a dynamic, clinical-stage life sciences company dedicated to pioneering advancements in central nervous system therapeutics. With a focus on overcoming barriers like the blood-brain barrier, NeOnc’s NEO™ drug development platform has yielded a range of innovative drug candidates and delivery methods, alongside patent protections that extend through to 2038. The company’s proprietary chemotherapy agents have shown encouraging results in laboratory evaluations and clinical trials targeting various cancers. The NEO100™ and NEO212™ therapeutics are currently progressing through Phase II human clinical trials, backed by FDA Fast-Track and Investigational New Drug (IND) statuses. NeOnc has also secured extensive licensing of worldwide patents from the University of Southern California, covering both issued patents and pending applications related to its primary products, showcasing its resilience in addressing oncological and neurological challenges.
Frequently Asked Questions
What is NeOnc Technologies known for?
NeOnc Technologies is recognized for its focus on developing novel therapies for oncology and neurology, particularly addressing the challenges of the blood-brain barrier.
How many patents does NeOnc currently hold?
The company holds a total of 176 patents, consisting of both issued and pending patents, to secure its innovations.
What are the lead programs of NeOnc Technologies?
NeOnc's lead programs include NEO100, NEO212, NEO214, and NEO400, which focus on innovative treatments in oncology.
What does the company's patent portfolio signify?
The patent portfolio enhances NeOnc’s ability to protect its innovations and maximize the potential market impact of its therapeutic candidates.
Where can I learn more about NeOnc Technologies?
More information about NeOnc Technologies and its innovative technologies can be found by visiting their official website.
